Customize HULK2 Antibody

Description

Clarification on Terminology and Potential Nomenclature Overlaps

HHLA2 (Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2): A member of the B7 immune checkpoint family, HHLA2 has been studied extensively in cancer immunology. It is structurally and functionally distinct from hypothetical "HULK2" but represents a critical immune regulator (see Tables 1–2) .
HuMab-5B1: A monoclonal antibody targeting CA19-9 for pancreatic cancer diagnostics and imaging (Phase I trial: NCT04883775) .
MAb 6F12: A pan-H1 influenza antibody targeting conserved hemagglutinin stalk regions with cross-neutralizing activity .

Key Findings on HHLA2 as a Comparative Case Study

While HHLA2 is not synonymous with "HULK2," its research framework exemplifies the depth of analysis required for novel antibodies.

Table 2: Methodological Validation of HHLA2 Studies

Technique	Application	Outcome
RandomForest Analysis	Identified HHLA2 as the top prognostic immune checkpoint in hepatocellular carcinoma	Variable importance = 1 (highest ranking)
Multiplex Immunofluorescence	Quantified immune cell infiltration in HHLA2-high vs. low tumors	Confirmed immunosuppressive microenvironment
qRT-PCR/IHC	Validated HHLA2 overexpression in 66.67% of HCC tissues vs. controls	P < 0.01

Research Gaps and Recommendations

The absence of data on "HULK2 Antibody" highlights the need for:

Terminal Verification: Confirm the correct nomenclature or target epitope. Potential typographical errors (e.g., HHLA2 vs. HULK2) should be cross-checked.
Exploratory Studies: If "HULK2" refers to a novel or proprietary antibody, foundational research (e.g., epitope mapping, in vitro neutralization assays) would be required to establish its biological role.
Comparative Analysis: Benchmark against established antibodies (e.g., anti-HHLA2, anti-GD2) to identify functional parallels or unique mechanisms.

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

HULK2 antibody; At2g48160 antibody; F11L15.6 antibody; Protein HUA2-LIKE 2 antibody; HUA2-like protein 2 antibody

Target Names

HULK2

Uniprot No.

F4IN78

Target Background

Function

HULK2 Antibody targets a probable transcription factor exhibiting partial redundancy with HULK1 and HULK3. It plays diverse and essential roles in regulating plant development, physiology, and flowering time.

Database Links

KEGG: ath:AT2G48160

STRING: 3702.AT2G48160.1

UniGene: At.27581

Subcellular Location

Nucleus.

Tissue Specificity

Expressed throughout young primordia, and vegetative and reproductive apices.

Q&A

Here’s a structured collection of FAQs tailored for researchers working with the HULK2 antibody, synthesized from peer-reviewed methodologies and experimental data:

Advanced Research Questions

How to resolve contradictory data on HULK2’s role in cellular cytotoxicity?

Analytical framework:

Variable	Confounding Factor	Resolution Strategy
ADCC activity	FcγRIIIa polymorphism	Use effector-enhanced IgG variants (e.g., G236A/S239D mutations)
Tumor models	Host immune cell depletion	Compare SCID (NK+/monocyte+) vs. SCID/NOD (NK–/monocyte–) mice

Apply finite mixture models to analyze skewed antibody-response distributions and identify latent subpopulations .

What in vivo models best characterize HULK2 antibody effector functions?

Design considerations:
- Use xenograft models with humanized FcγR mice to study ADCC .
- Monitor tumor volume reduction kinetics (e.g., ≥6.2-fold in SCID vs. 1.6-fold in SCID/NOD mice) .
- Pair with multiplex cytokine profiling to assess immune activation (e.g., IFN-γ, Granzyme B) .

How to address batch-to-batch variability in HULK2 antibody production?

Quality control pipeline:
- Binding kinetics: Validate via SPR (e.g., KD ≤10 nM for high-affinity clones) .
- Functional consistency: Standardize ADCC assays using NK-92MI effector cells at 50:1 E:T ratio .
- Epitope stability: Perform differential scanning calorimetry (DSC) to assess thermal denaturation profiles .

Data Analysis & Interpretation

How to statistically analyze HULK2 antibody multiplex assay data?

Recommended workflow:
- Preprocess data using Box-Cox transformation to correct skewness in seropositive populations .
- Apply Bayesian mixture models to distinguish specific vs. nonspecific binding signals .
- For longitudinal studies, use mixed-effects models to account for antibody decay rates .

What computational tools predict HULK2-antibody cross-reactivity?

Resources:
- Structural modeling: RosettaAntibody for paratope-epitope docking simulations .
- Phylogenetic analysis: BLAST alignment against UniProt’s immunoglobulin database to identify conserved motifs .

Experimental Design Tables

Table 1: HULK2 Antibody Validation Checklist

Parameter	Assay	Acceptance Criteria
Specificity	Western blot (KO vs. WT)	No band in KO lysate
Affinity	SPR/BLI	KD ≤10 nM
Functional activity	ADCC (NK cell assay)	≥50% target lysis at 10 µg/mL

Table 2: In Vivo Efficacy Metrics

Model	Tumor Suppression (vs. control)	Key Immune Metrics
SCID	6.2-fold reduction	CD107a+ NK cells ↑2.5x
SCID/NOD	1.6-fold reduction	No significant NK activation

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

HULK2 Antibody